Table 1 Characteristics of prostate patients in the RADIOGEN cohort

Age

Mean [Min, Max]

71.0 [55.0, 83.0]

70.7 [57.0, 82.0]

0.005 [0.73]^a

70.9 [55.0, 83.0]

Frozen blood sample

Yes

32 (61.5%)

36 (67.9%)

0.119 [0.39]

68 (64.8%)

Weight

Mean [Min, Max]

78.1 [60.0, 103]

79.4 [53.0, 111]

0.006 [0.37]^a

78.8 [53.0, 111]

Missing

1 (1.9%)

0 (0%)

–

1 (1.0%)

Smoker status

Never

24 (46.2%)

27 (50.9%)

51 (48.6%)

Former

23 (44.2%)

20 (37.7%)

− 0.067 [0.53]

43 (41.0%)

Current

5 (9.6%)

6 (11.3%)

0.088 [0.93]

11 (10.5%)

Alcohol intake

Never

16 (30.8%)

14 (26.4%)

30 (28.6%)

Former

7 (13.5%)

11 (20.8%)

0.026 [0.90]

18 (17.1%)

Current

28 (53.8%)

27 (50.9%)

0.008 [0.96]

55 (52.4%)

Missing

1 (1.9%)

1 (1.9%)

–

2 (1.9%)

Diabetes

Yes

9 (17.3%)

11 (20.8%)

0.114 [0.53]

20 (19.0%)

Hypertension

Yes

32 (61.5%)

29 (54.7%)

− 0.213 [0.18]

61 (58.1%)

History of Heart disease

Yes

8 (15.4%)

11 (20.8%)

0.149 [0.43]

19 (18.1%)

Haemorrhoids

Yes

8 (15.4%)

4 (7.5%)

− 0.181 [0.35]

12 (11.4%)

Depression

Yes

3 (5.8%)

0 (0%)

− 0.745 [0.13]

3 (2.9%)

On ACE inhibitor?

Yes

18 (34.6%)

16 (30.2%)

− 0.013 [0.94]

34 (32.4%)

On Beta blocker?

Yes

9 (17.3%)

11 (20.8%)

0.046 [0.81]

20 (19.0%)

On 5-alpha reductase inhibitor?

Yes

1 (1.9%)

2 (3.8%)

0.104 [0.78]

3 (2.9%)

On alpha blocker?

Yes

10 (19.2%)

7 (13.2%)

− 0.220 [0.27]

17 (16.2%)

Clinical T stage

 < T2a

25 (48.1%)

30 (56.6%)

55 (52.4%)

 > T2b

26 (50%)

22 (41.5%)

− 0.113 [0.47]

48 (45.7%)

Missing

1 (1.9%)

1 (1.9%)

–

2 (1.9%)

Clinical N stage

N0

26 (50.0%)

32 (60.4%)

58 (55.2%)

N1

3 (5.8%)

0 (0%)

− 0.553 [0.06]

3 (2.9%)

Nx

23 (44.2%)

21 (39.6%)

− 0.077 [0.44]

44 (41.9%)

M stage

M0

30 (57.7%)

33 (62.3%)

63 (60.0%)

Mx

22 (42.3%)

20 (37.7%)

− 0.028 [0.80]

42 (40.0%)

TURP

Yes

1 (1.9%)

1 (1.9%)

0.328 [0.50]

2 (1.9%)

Radical Prostatectomy

Yes

18 (34.6%)

15 (28.3%)

0.085 [0.80]

33 (31.4%)

Lymphadenectomy

Yes

3 (5.8%)

3 (5.7%)

0.096 [0.78]

6 (5.7%)

Gleason Score

 ≤ 7

45 (86.5%)

49 (92.2%)

94 (89.5%)

 ≥ 8

7 (13.4%)

4 (7.5%)

11 (10.4%)

PSA prediagnostic (ng/mL)

Mean [Min, Max]

10.8 [3.00, 58.0]

15.8 [3.42, 95.5]

0.005 [0.40]^a

13.3 [3.00, 95.5]

Hormone therapy

Yes

28 (53.8%)

26 (49.1%)

0.012 [0.95]

54 (51.4%)

RT interrupted

Yes

1 (1.9%)

1 (1.9%)

− 0.383 [0.51]

2 (1.9%)

RT type

3D-CRT

52 (100%)

53 (100%)

NA

105 (100%)

RT external beam dose (Gy)

Mean [Min, Max]

69.6 [37.5, 76.0]

67.7 [24.0, 76.0]

0.030 [0.43]^a

68.6 [24.0, 76.0]

Missing

0 (0%)

1 (1.9%)

–

1 (1.0%)

PTV (cm³)

Mean [Min, Max]

135 [65.0, 241]

164 [71.0, 993]

0.002 [0.46]^a

149 [65.0, 993]

Missing

0 (0%)

1 (1.9%)

–

1 (1.0%)

CTV (cm³)

Mean [Min, Max]

44.9 [15.0, 103]

45.6 [18.0, 89.0]

− 0.001 [0.87]^a

45.3 [15.0, 103]

Missing

0 (0%)

2 (3.8%)

–

2 (1.9%)

Dose per fraction (Gy)

2

47 (90.4%)

46 (86.8%)

93 (88.6%)

2.5

5 (9.6%)

6 (11.3%)

1.461 [0.60]

11 (10.5%)

Missing

0 (0%)

1 (1.9%)

–

1 (1.0%)

Pelvic RT

Yes

7 (13.5%)

6 (11.3%)

− 0.119 [0.61]

13 (12.4%)

Missing

0 (0%)

1 (1.9%)

–

1 (1.0%)

Pelvic RT dose (Gy)

Mean [Min, Max]

46.3 [44.0, 50.0]

46.0 [46.0, 46.0]

NA

46.2 [44.0, 50.0]

RT Rectum V65Gy (%)

Mean [Min, Max]

15.0 [0, 48.0]

11.0 [0, 29.0]

− 0.020 [0.04]^a

13.0 [0, 48.0]

Missing

1 (1.9%)

1 (1.9%)

–

2 (1.9%)

RT Bladder V60Gy (%)

Mean [Min, Max]

18.9 [0, 56.0]

14.9 [0, 54.0]

− 0.007 [0.29]^a

16.9 [0, 56.0]

Missing

1 (1.9%)

1 (1.9%)

–

2 (1.9%)